KEY TAKEAWAYS FROM THE U.S. SUPREME COURT’S PATENT DECISION REGARDING PRIOR ART AND SECRET SAL

Nearly eight years after the passage into law of the America Invents Act of 2011 (AIA), the U.S. Supreme Court is still weighing in on the historic reform’s impact on established patent law. In a closely watched case within the patent community, in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., U.S., No. 17-1229 (Jan 22, 2019) the High Court ruled that the AIA did not upset long-understood interpretations of how sales of a patented product—even if kept confidential—could be cited as prior art to invalidate an issued patent. There are several lessons patent applicants, owners, and challengers of patents can take from this decision.

Read entire article here.

0 views0 comments

Recent Posts

See All

In an increasingly globalized world, it is extremely important to understand what is involved in enforcing judgments against foreign assets. Given that there is no global system for enforcing a judgme